Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial

Health Care

Health Care Recent News

5 Stocks Investors Couldn't Stop Buzzing About This Week: AAPL, GOOG, HOOD And More
5 Stocks Investors Couldn't Stop Buzzing About This Week: AAPL, GOOG, HOOD And More
Retail investors talked up five hot stocks this week (April 27 to May 1) on X and Reddit's r/WallStreetBets: AAPL, GOOG, HOOD, META, LLY.
S&P 500's Best‑Kept Secret: Why Healthcare Could Be 2026's Breakout Winner
S&P 500's Best‑Kept Secret: Why Healthcare Could Be 2026's Breakout Winner
AI‑powered drug discovery, strong earnings upgrades, and rising institutional flows show why healthcare may shift from 2026 laggard to breakout S&P 500 growth story.
BrightSpring Extends Rally With Solid Q1, Upgraded Fiscal 2026 Forecast
BrightSpring Extends Rally With Solid Q1, Upgraded Fiscal 2026 Forecast
BrightSpring shares rise after Q1 earnings beat, revenue growth and raised FY26 guidance; analysts cite momentum but note valuation premium.
Trump Taps Nicole Saphier As Surgeon General Pick, Withdraws Casey Means' Nomination
Trump Taps Nicole Saphier As Surgeon General Pick, Withdraws Casey Means' Nomination
Dr. Nicole Saphier is nominated by Trump as U.S. Surgeon General in his third attempt to fill top health post.
Seaport Therapeutics Set For Nasdaq Debut After Raising $255 Million In IPO
Seaport Therapeutics Set For Nasdaq Debut After Raising $255 Million In IPO
Seaport Therapeutics priced its upsized IPO at $18 per share to raise roughly $255 million, signaling continued investor appetite for early-stage biotech companies.
Tenet Healthcare Blames Admissions Mix For Soft Q1 Sales
Tenet Healthcare Blames Admissions Mix For Soft Q1 Sales
Tenet Healthcare posts Q1 earnings beat but revenue miss as payer mix shifts and external disruptions weigh on performance.
Merck Swings To Quarterly Loss On Cidara Deal
Merck Swings To Quarterly Loss On Cidara Deal
Merck Q1 2026 results show oncology-led growth, vaccine weakness, and raised guidance after beating sales and loss estimates.
Labcorp Advances As AI Investments, Core Businesses Drive Growth
Labcorp Advances As AI Investments, Core Businesses Drive Growth
Labcorp shares rise after Q1 earnings beat and higher guidance, supported by diagnostics growth and investments in AI and robotics.
Eli Lilly Raises 2026 Outlook On Strong Mounjaro And Zepbound Demand
Eli Lilly Raises 2026 Outlook On Strong Mounjaro And Zepbound Demand
Eli Lilly beats Q1 estimates, lifts 2026 outlook as Mounjaro and Zepbound demand offsets pricing pressure and drives strong revenue growth.
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and plans accelerated execution in 2026.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved